PL3207938T3 - Warianty CTLA-4 - Google Patents

Warianty CTLA-4

Info

Publication number: PL3207938T3
Authority: PL; Poland
Prior art keywords: ctla; variants
Prior art date: 2012-05-11

Application number

PL17163638T

Other languages

English (en)

Inventor

Ralph Minter

Julie DOUTHWAITE

Jacques Moisan

Michael Bowen

Steven RUST

Cyril PRIVESENTZEV

Original Assignee

Medimmune Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-11

Filing date

2013-03-11

Publication date

2020-07-13

2013-03-11 Application filed by Medimmune Limited filed Critical Medimmune Limited

2020-07-13 Publication of PL3207938T3 publication Critical patent/PL3207938T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C07K14/425—Zeins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Cell Biology (AREA)
Zoology (AREA)
Toxicology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Transplantation (AREA)
Biomedical Technology (AREA)
Botany (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL17163638T 2012-05-11 2013-03-11 Warianty CTLA-4 PL3207938T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201261645686P	2012-05-11	2012-05-11
EP17163638.4A EP3207938B1 (en)	2012-05-11	2013-03-11	Ctla-4 variants
EP13787673.6A EP2863936A4 (en)	2012-05-11	2013-03-11	CTLA-4 VARIANTS
PCT/US2013/030179 WO2013169338A1 (en)	2012-05-11	2013-03-11	Ctla-4 variants

Publications (1)

Publication Number	Publication Date
PL3207938T3 true PL3207938T3 (pl)	2020-07-13

Family

ID=49551120

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17163638T PL3207938T3 (pl)	2012-05-11	2013-03-11	Warianty CTLA-4

Country Status (17)

Country	Link
US (2)	US9884902B2 (pl)
EP (2)	EP3207938B1 (pl)
JP (1)	JP6228971B2 (pl)
KR (1)	KR102133060B1 (pl)
CN (2)	CN104302309B (pl)
AU (1)	AU2013260172B2 (pl)
BR (1)	BR112014026718B1 (pl)
CA (1)	CA2868748C (pl)
DK (1)	DK3207938T3 (pl)
ES (1)	ES2777778T3 (pl)
HK (1)	HK1209644A1 (pl)
HU (1)	HUE048925T2 (pl)
MX (1)	MX355234B (pl)
PL (1)	PL3207938T3 (pl)
RU (1)	RU2671465C2 (pl)
SG (2)	SG10201609447XA (pl)
WO (1)	WO2013169338A1 (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL3207938T3 (pl) *	2012-05-11	2020-07-13	Medimmune Limited	Warianty CTLA-4
PT2867251T (pt) *	2012-06-29	2019-11-11	Bristol Myers Squibb Co	Métodos para reduzir a agregação de glicoproteínas
US9944689B2 (en) *	2013-03-07	2018-04-17	The General Hospital Corporation	Human CTLA4 mutants and use thereof
KR20160113268A (ko) *	2014-01-28	2016-09-28	베이징 한미 파마슈티컬 컴퍼니 리미티드	이기능 융합단백질,이의 제조방법 및 용도
EP3244907B1 (en)	2015-01-13	2020-02-19	City of Hope	Ctla4-binding protein peptide-linker masks
MA41459A (fr)	2015-02-03	2017-12-12	Als Therapy Development Inst	Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
CN114773486A (zh)	2015-04-17	2022-07-22	高山免疫科学股份有限公司	具有可调的亲和力的免疫调节蛋白
US11351224B2 (en)	2015-08-21	2022-06-07	Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University)	Pharmaceutical composition for preventing and treating transplant rejection
US11053295B2 (en)	2015-08-21	2021-07-06	Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University)	Peptides having effects of preventing or treating central nervous system diseases and pharmaceutical compositions for preventing or treating central nervous system diseases containing same as active ingredient
WO2017034244A1 (ko) *	2015-08-21	2017-03-02	한양대학교 산학협력단	중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
KR20180054713A (ko) *	2015-09-14	2018-05-24	알파인 이뮨 사이언시즈, 인코포레이티드	조율가능한 변종 면역글로불린 수퍼패밀리 도메인 및 유전자 조작된 세포 치료법
CN108367069B (zh)	2015-12-14	2022-08-23	宏观基因有限公司	对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
KR101918456B1 (ko) *	2015-12-15	2018-11-16	앱클론(주)	Cd80 및 cd86에 특이적으로 결합하는 항체
AU2017248830B2 (en)	2016-04-15	2023-03-09	Alpine Immune Sciences, Inc.	CD80 variant immunomodulatory proteins and uses thereof
EP3442999A2 (en)	2016-04-15	2019-02-20	Alpine Immune Sciences, Inc.	Icos ligand variant immunomodulatory proteins and uses thereof
US11471488B2 (en)	2016-07-28	2022-10-18	Alpine Immune Sciences, Inc.	CD155 variant immunomodulatory proteins and uses thereof
US11834490B2 (en)	2016-07-28	2023-12-05	Alpine Immune Sciences, Inc.	CD112 variant immunomodulatory proteins and uses thereof
CN110662758A (zh)	2017-03-16	2020-01-07	高山免疫科学股份有限公司	Cd80变体免疫调节蛋白及其用途
CA3053812A1 (en)	2017-03-16	2018-09-20	Alpine Immune Sciences, Inc.	Pd-l2 variant immunomodulatory proteins and uses thereof
RU2770209C2 (ru)	2017-05-24	2022-04-14	ЭйЭлЭс ТЕРАПИ ДЕВЕЛОПМЕНТ ИНСТИТЬЮТ	Терапевтические антитела против лиганда cd40
US11753458B2 (en)	2017-10-10	2023-09-12	Alpine Immune Sciences, Inc.	CTLA-4 variant immunomodulatory proteins and uses thereof
EP3697810A2 (en)	2017-10-18	2020-08-26	Alpine Immune Sciences, Inc.	Variant icos ligand immunomodulatory proteins and related compositions and methods
WO2019241758A1 (en)	2018-06-15	2019-12-19	Alpine Immune Sciences, Inc.	Pd-1 variant immunomodulatory proteins and uses thereof
JP2022505045A (ja) *	2018-11-02	2022-01-14	ベイジンブイディージェイバイオカンパニー，リミテッド	修飾されたｃｔｌａ４およびその使用方法
US20220153805A1 (en) *	2019-04-10	2022-05-19	University Of Kentucky Research Foundation	A Novel Prostate Apoptosis Response-4 (Par-4) Protein Entity with an Extended Duration of Action for Therapeutic Treatment of Cancer
AU2021205976A1 (en) *	2020-01-11	2022-07-07	Yale University	Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with DNAse1 and/or DNAse1L3 deficiency
CN115667292A (zh) *	2020-04-06	2023-01-31	朗格生物技术公共公益股份有限公司	模块化合成受体和使用方法
AU2022361768A1 (en) *	2021-10-08	2024-05-02	Kashiv Biosciences, Llc	Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
WO2023057994A1 (en) *	2021-10-08	2023-04-13	Kashiv Biosciences, Llc	Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
AU2022414315A1 (en) *	2021-12-17	2024-07-25	Kashiv Biosciences, Llc	An improved assay method for determining the potency of recombinant protein
TW202342510A (zh)	2022-02-18	2023-11-01	英商Ｒｑ生物科技有限公司	抗體
WO2024211211A1 (en)	2023-04-03	2024-10-10	Regeneron Pharmaceuticals, Inc.	Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2123001T5 (es)	1991-06-27	2009-04-16	Bristol-Myers Squibb Company	Receptor ctl4a, proteinas de fusion que lo contienen y sus usos.
US6750334B1 (en)	1996-02-02	2004-06-15	Repligen Corporation	CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
AU3804397A (en) *	1996-06-14	1998-01-07	Smithkline Beecham Corporation	Hexameric fusion proteins and uses therefor
BRPI0111191B8 (pt) *	2000-05-26	2021-05-25	Bristol Myers Squibb Co	moléculas mutantes de ctla4 solúveis, método para sua produção e seus usos
US7094874B2 (en)	2000-05-26	2006-08-22	Bristol-Myers Squibb Co.	Soluble CTLA4 mutant molecules
US20040132101A1 (en) *	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US7563443B2 (en) *	2004-09-17	2009-07-21	Domantis Limited	Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2007007654A1 (ja)	2005-07-07	2007-01-18	Toshiba Lighting & Technology Corporation	放電灯点灯装置および電球形蛍光ランプ
GB0620934D0 (en) *	2006-10-20	2006-11-29	Cambridge Antibody Tech	Protein variants
EP2612867A1 (en)	2007-11-01	2013-07-10	Perseid Therapeutics LLC	Immunosuppressive polypeptides and nucleic acids
JP5705242B2 (ja) *	2010-02-19	2015-04-22	ゼンコアインコーポレイテッド	新規ｃｔｌａ４−ｉｇ免疫アドヘシン
CN102822198B (zh) *	2010-03-12	2016-08-31	艾伯维生物医疗股份有限公司	Ctla4蛋白和其用途
PL3207938T3 (pl) *	2012-05-11	2020-07-13	Medimmune Limited	Warianty CTLA-4

2013
- 2013-03-11 PL PL17163638T patent/PL3207938T3/pl unknown
- 2013-03-11 HU HUE17163638A patent/HUE048925T2/hu unknown
- 2013-03-11 CN CN201380024763.3A patent/CN104302309B/zh active Active
- 2013-03-11 AU AU2013260172A patent/AU2013260172B2/en active Active
- 2013-03-11 JP JP2015511443A patent/JP6228971B2/ja active Active
- 2013-03-11 WO PCT/US2013/030179 patent/WO2013169338A1/en active Application Filing
- 2013-03-11 CA CA2868748A patent/CA2868748C/en active Active
- 2013-03-11 EP EP17163638.4A patent/EP3207938B1/en active Active
- 2013-03-11 CN CN201710735648.7A patent/CN107540742B/zh active Active
- 2013-03-11 US US14/399,685 patent/US9884902B2/en active Active
- 2013-03-11 SG SG10201609447XA patent/SG10201609447XA/en unknown
- 2013-03-11 RU RU2014150092A patent/RU2671465C2/ru active
- 2013-03-11 DK DK17163638.4T patent/DK3207938T3/da active
- 2013-03-11 KR KR1020147031064A patent/KR102133060B1/ko active IP Right Grant
- 2013-03-11 MX MX2014013092A patent/MX355234B/es active IP Right Grant
- 2013-03-11 BR BR112014026718-9A patent/BR112014026718B1/pt active IP Right Grant
- 2013-03-11 SG SG11201405968SA patent/SG11201405968SA/en unknown
- 2013-03-11 EP EP13787673.6A patent/EP2863936A4/en not_active Withdrawn
- 2013-03-11 ES ES17163638T patent/ES2777778T3/es active Active
2015
- 2015-10-28 HK HK15110585.3A patent/HK1209644A1/xx unknown
2017
- 2017-12-21 US US15/850,990 patent/US20180208639A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20150104450A1 (en)	2015-04-16
CN107540742A (zh)	2018-01-05
HK1209644A1 (en)	2016-04-08
CA2868748C (en)	2022-07-26
CN107540742B (zh)	2021-06-29
AU2013260172B2 (en)	2017-11-23
CN104302309B (zh)	2017-07-28
HUE048925T2 (hu)	2020-09-28
CN104302309A (zh)	2015-01-21
SG11201405968SA (en)	2014-11-27
CA2868748A1 (en)	2013-11-14
DK3207938T3 (da)	2020-03-16
EP3207938A2 (en)	2017-08-23
EP2863936A1 (en)	2015-04-29
US9884902B2 (en)	2018-02-06
EP3207938B1 (en)	2019-12-25
JP6228971B2 (ja)	2017-11-08
ES2777778T3 (es)	2020-08-06
AU2013260172A1 (en)	2014-10-23
RU2671465C2 (ru)	2018-10-31
SG10201609447XA (en)	2017-01-27
KR20150014443A (ko)	2015-02-06
EP2863936A4 (en)	2016-10-05
RU2014150092A (ru)	2016-07-10
BR112014026718B1 (pt)	2021-05-18
BR112014026718A2 (pt)	2017-07-18
JP2015523328A (ja)	2015-08-13
WO2013169338A1 (en)	2013-11-14
KR102133060B1 (ko)	2020-07-10
MX2014013092A (es)	2015-03-03
EP3207938A3 (en)	2017-11-01
US20180208639A1 (en)	2018-07-26
MX355234B (es)	2018-04-11

Publication	Publication Date	Title
HK1209644A1 (en)	2016-04-08	Ctla-4 variants ctla-4
HK1215183A1 (zh)	2016-08-19	蛋白質-聚合物-藥物共軛物
GB201304182D0 (en)	2013-04-24	No details
DK3327112T3 (en)	2020-05-04	Agse-deficient stamme
GB201403961D0 (en)	2014-04-23	No details
DK2830816T3 (en)	2020-02-17	Hidtil ukendt coatingkoncept
GB201411220D0 (en)	2014-08-06	No details
GB201420527D0 (en)	2014-12-31	Electrical-wire-protecting member
GB2518076B (en)	2017-09-06	Electrical-wire-protecting member
PL2864290T3 (pl)	2017-11-30	3-o-heteroaryloingenol
GB201313844D0 (en)	2013-09-18	No details
GB201403415D0 (en)	2014-04-16	No details
GB201305860D0 (en)	2013-05-15	Pro-Pos
GB201322955D0 (en)	2014-02-12	No details
GB201400108D0 (en)	2014-02-19	No details
GB201302155D0 (en)	2013-03-27	No details
GB201300109D0 (en)	2013-02-20	No details
GB201310646D0 (en)	2013-07-31	No details
GB201304445D0 (en)	2013-04-24	Innovo
IL224081B (en)	2019-10-31	Show-my-face
GB201220309D0 (en)	2012-12-26	Gapstep
AU345893S (en)	2012-12-04	Treehouse
GB201219438D0 (en)	2012-12-12	Scompass
GB201218297D0 (en)	2012-11-28	MyCatIsFat
GB201216246D0 (en)	2012-10-24	Coolflip